Clinical trial · Interventional
Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)
Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. A Qualitative Cross-sectional Study of Professionals, Patients, Parents of Sick Children, and Expert Patients, in the Context of Triple Negative or Luminal B Breast Cancer, Metastatic Uveal Melanoma and Pediatric Cancers.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Resistance to treatment is one of the major themes in cancer research. Despite this, the definition and clinical implications of resistance to treatment remain under-explored, and patient-physician communication in this context still constitutes a challenge. When resistance to cancer treatments occurs, physicians not only have to explain to the patient the phenomenon of resistance, often based on complex results (biological results, genomic tests, imaging, etc.), but also need to offer alternative therapies, whilst fostering shared medical decision-making. These different tasks are particularly challenging for clinicians, especially since there are large individual differences at patient level. Indeed, each patient has his or her own unique information needs, capacity for understanding, and level of desire to participate in treatment decisions.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Luminal B Breast Cancer | Luminal B Breast Carcinoma | ALIAS | 0.90 |
| Metastatic Uveal Melanoma | Uveal Melanoma | CURATED_BROADER | 0.78 |
| Pediatric Cancer | Childhood Malignant Neoplasm | ALIAS | 0.90 |
| Triple Negative Breast Cancer | Triple-Negative Breast Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DELPHI Consensus Method | Other | — | UNRESOLVED |
| Focus Group | Other | — | UNRESOLVED |
| Questionnaires | Behavioral | — | UNRESOLVED |
| Semi-structured individual interviews | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (6)
- type
- OTHER
- label
- Metastatic Uveal Melanoma
- description
- Questionnaires and semi-structured individual interviews with patients with Metastatic Uveal Melanoma
- interventionNames
- Behavioral: Questionnaires
- Behavioral: Semi-structured individual interviews
- type
- OTHER
- label
- Triple Negative Breast Cancer
- description
- Questionnaires and semi-structured individual interviews with patients with Triple Negative Breast Cancer
- interventionNames
- Behavioral: Questionnaires
- Behavioral: Semi-structured individual interviews
- type
- OTHER
- label
- Luminal B Breast Cancer
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients: 1. To be 18 years of age or older ; 2. To have metastatic uveal melanoma (MUM) or triple negative or luminal B breast cancer ; 3. To have received the information that the disease is resistant to treatment ; 4. To have read the information and signed the informed consent. * Parents of a sick child: 1. To be a parent (parental authority holder) of a child with cancer ; 2. To have received the information that the child disease is resistant to treatment ; 3. To have read the information and signed the informed consent. * Expert patients: 1. To be 18 years of age or older ; 2. To have had cancer (regardless the cancer site) ; 3. To participated to an expert patient training (fine knowledge of the illness, experience with the disease) ; 4. To have read the information and signed the informed consent. * Professionals: 1. To be an oncologist (medical oncologist, surgeon, radiotherapist, supportive care specialist) and/or to be a researcher in oncology (doctor, biologist, geneticist ...) ; 2. To have patients with a triple-negative or luminal B breast cancer or metastatic uveal melanoma which is resistant to anti-tumor treatments and/or to take part to a research on resistance to cancer treatment; 3. To have read the information and signed the informed consent. Exclusion Criteria: * Patients \& parents of a sick child: 1. To have difficulties in understanding the French language. 2. Have or have had cancer (criteria only for parents); 3. Pregnant woman, likely to be pregnant or breastfeeding (criteria only for patients). 4. Persons deprived of their liberty or under guardianship; 5. Impossibility of study requirements respect for geographical, social or psychological reasons. * Expert patients: 1. To have difficulties in understanding the French language ; 2. Currently being undergoing anti-tumor treatment. * Professionals: 1. To have difficulties in understanding the French language ; 2. Not to be confronted in professional practice with resistance to anti-tumor treatments.
References
Publications (2)
- DERIVEDRault A, Dolbeault S, Terrasson J, Bouleuc C, Cottu P, Piperno-Neumann S, Rodrigues M, Vaflard P, Bredart A. Facilitating patient-oncologist communication in advanced treatment-resistant cancer: development and feasibility testing of a question prompt list. Pilot Feasibility Stud. 2024 Aug 28;10(1):116. doi: 10.1186/s40814-024-01543-y. PMID 39198868
- DERIVEDBredart A, Rault A, Terrasson J, Seigneur E, De Koning L, Hess E, Savignoni A, Cottu P, Pierga JY, Piperno-Neumann S, Rodrigues M, Bouleuc C, Dolbeault S. Helping Patients Communicate With Oncologists When Cancer Treatment Resistance Occurs to Develop, Test, and Implement a Patient Communication Aid: Sequential Collaborative Mixed Methods Study. JMIR Res Protoc. 2022 Jan 12;11(1):e26414. doi: 10.2196/26414. PMID 35019850